Pharmacokinetic Study to Determine Time to Steady-state

Status Completed

Clinical Trial Summary

The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.

Clinical Trial Description

Serum testosterone levels will be obtained in hypogonadal (serum testosterone <300 ng/dL) males receiving testosterone undecanoate capsules administered twice daily. Serum samples will be obtained consecutively in the morning on several days during one month of open-label treatment to confirm the time at which steady-state is reached. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00911586
Study type	Interventional
Source	Clarus Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	July 2009
Completion date	January 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01454011` - The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups	Phase 4
Completed	`NCT01191320` - Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus	Phase 2
Completed	`NCT01739595` - Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism	Phase 3
Completed	`NCT01739582` - An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism	Phase 3
Active, not recruiting	`NCT02443090` - Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men	Phase 2
Completed	`NCT01534208` - Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism	Phase 3
Completed	`NCT00467870` - Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men	Phase 3
Completed	`NCT00962637` - Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism	Phase 3
Completed	`NCT01067365` - Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism	Phase 3
Completed	`NCT01386606` - The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)	Phase 2
Completed	`NCT00706719` - To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone	Phase 2
Completed	`NCT01993225` - A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%	Phase 3
Completed	`NCT01993212` - A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%	Phase 3
Completed	`NCT01270841` - Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism	Phase 2
Completed	`NCT02274181` - An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration	Phase 1
Completed	`NCT01923870` - Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function	Phase 1
Completed	`NCT01923857` - Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function	Phase 1
Completed	`NCT01532414` - Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism	Phase 3